Chiesi Launches $27.00/Share Tender Offer for KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) signed a definitive merger agreement on April 28, 2026 to be acquired by Chiesi Farmaceutici S.p.A., the privately held, family-controlled Italian pharma based in Parma. Chiesi's Delaware merger sub, Skyline Merger Sub, Inc., will commence a tender offer for all outstanding KALV shares at $27.00 per share in cash. The first formal SEC filing is the SC TO-C preliminary communication dated May 5, 2026; the actual Schedule TO is expected within ten business days of signing.

The Offer

The deal values KalVista's equity at approximately $1.9 billion. KalVista is a commercial-stage biopharma whose lead asset is EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE) attacks, which received FDA approval in mid-2025 and generated about $49 million in 2025 sales. The KalVista board unanimously approved the merger and resolved to recommend that stockholders tender into Chiesi's offer.

The $27.00 price is a 40% premium to KalVista's $19.24 close on April 28, 2026 (the last unaffected trading day) and a 36% premium to the 30-day volume-weighted average price, the figure quoted in the joint press release. KALV last printed at $26.73, $0.27 below the offer — a spread of about 1.0%.

Why This Is Interesting

This is a clean, fully-funded cash deal with a unanimous board recommendation and no contingent consideration. For tender-offer arbitrage players, the spread is narrow but the risk profile is unusually benign: no financing condition, no shareholder vote (Section 251(h) handles the back end), no U.S. CFIUS overhang, and an acquirer with a clear strategic rationale (rare-disease franchise expansion, U.S. commercial footprint, and progress toward Chiesi's stated 2030 €6 billion revenue target).

The catch — and it is a small one — is that the offer hasn't formally commenced yet. Until Chiesi files the Schedule TO and KalVista files its Schedule 14D-9, you cannot actually tender. With the deal expected to close in Q3 2026, the annualized return on the current 1.0% spread is roughly 4-6% depending on exact timing. That's not a windfall, but for cash that would otherwise sit in a money market, it's an attractive parking spot.

Worth flagging up front: there is no odd-lot provision disclosed. Holders of fewer than 100 shares get no preferential treatment here — all shareholders sit in the same queue. That removes the cleanest small-investor angle this site usually surfaces.

Key Terms

Why Chiesi Wants KalVista

EKTERLY (sebetralstat) is the strategic prize. Until its FDA approval, every approved on-demand HAE therapy required injection or infusion — Takeda's Firazyr (icatibant subcutaneous injection), CSL Behring's Berinert (IV C1 esterase inhibitor), and Pharvaris and Ionis programs that are still in development. EKTERLY is the first oral pill, which in a disease where attacks come on suddenly and unpredictably is a meaningful quality-of-life upgrade. The KONFIDENT Phase 3 trial showed faster symptom relief and attack resolution versus placebo, and the recent positive interim KONFIDENT-KID data extends the franchise toward children aged 2-11 with a planned U.S. NDA in Q3 2026.

For Chiesi — which generated €3.625 billion in 2025 revenue, ended the year with a positive net financial position of €729 million, and has been building a rare-disease franchise since its 2023 acquisition of Amryt Pharma — sebetralstat slots in as the largest commercial deal in its history. It also gives Chiesi a real U.S. commercial infrastructure for the first time at scale.

Will This Deal Close?

Short answer: almost certainly, yes. Walk through the standard close-or-die questions:

Board approval. The KalVista board unanimously approved the merger agreement and resolved to recommend that stockholders tender. Chiesi's board unanimously approved on its end as well. No dissenting directors, no special-committee drama.

Financing. Chiesi is privately held but it isn't capital-constrained. It generated €3.625 billion in 2025 revenue, grew 8.2% at constant FX, and finished 2025 with a positive net financial position of €729 million. The merger agreement contains no financing condition, which is the strongest signal you can ask for: Chiesi has either committed cash, committed debt, or both, and is not allowed to walk if a financing source falls through. The $1.9 billion ticket is large for Chiesi but well within the range of an investment-grade-style debt facility plus balance sheet cash, especially given the asset is already FDA-approved and revenue-producing.

Minimum tender condition. One more share than 50% of outstanding. That's a low bar for a deal at a 40% premium with a unanimous board recommendation — index funds and retail will do most of the work.

Regulatory. Three reviews are needed: U.S. HSR antitrust (routine for a deal where the acquirer doesn't compete in the HAE space), German Bundeskartellamt clearance (routine), and Italian foreign-investment clearance (Italy reviewing an Italian acquirer of a U.S. target — essentially a procedural sign-off rather than a substantive review). None of these has obvious teeth. There is no U.S. CFIUS process for an Italian buyer of a small-cap U.S. biotech with no defense or critical-tech footprint.

Termination fee and shop process. The $66.4 million break fee is roughly 3.5% of equity value — squarely market-standard. The agreement has customary no-solicitation language with a fiduciary out, but no go-shop window. A topping bid is theoretically possible (large pharma routinely circles HAE assets) but the 40% premium and unanimous board endorsement set a high bar for any interloper.

Net assessment: deal-completion risk is low. The 1.0% spread reflects that. The realistic risks are timing slippage (Q3 close drifting into Q4) and an extremely low-probability regulatory snag in Germany or Italy.

Deal Structure: Section 251(h) in Plain English

The transaction uses a Section 251(h) two-step structure. Step one: Chiesi runs a tender offer for all KALV shares; if more than 50% are tendered (along with the other conditions being met), Chiesi closes the offer and pays cash. Step two: Delaware's Section 251(h) lets Chiesi immediately squeeze out the remaining shares at the same $27.00 price without a separate shareholder vote. From a holder's standpoint: tender now and get paid quickly, or sit tight and get paid the same amount a few weeks later through the back-end merger. There is no benefit to holding out, and dissenters' rights are preserved either way.

Timeline

Risks

• Timing slippage — most likely risk. German or Italian regulatory clearance taking longer than expected pushes close from Q3 to Q4 2026, compressing annualized returns. Probability: moderate. Impact: small.
• Spread is thin — at $0.27 above the unaffected price's premium-adjusted level, you have very little cushion. If the deal breaks for any reason, KALV would likely retrace a large portion of the post-announcement gain. Implied downside is roughly 25-35% to the unaffected $19.24, possibly more given the stock was at the 52-week high already.
• No odd-lot preference — small holders get no special treatment, removing the cleanest low-risk angle for this audience.
• Topping bid — theoretically possible given HAE is a high-interest space, but the 40% premium plus unanimous board approval and a 3.5% break fee makes a competing offer unlikely. If one emerges, current holders would benefit, so this is upside risk rather than downside.
• Material adverse change — standard MAC clause in the merger agreement. KalVista's commercial momentum on EKTERLY makes a deal-breaking MAC event unlikely in the few months between signing and close.
• Antitrust surprise — low probability. Chiesi has no overlapping HAE products, so substantive overlap is minimal. A second request from any of the three reviewers would mostly affect timing rather than completion.

Bottom Line

If you don't already own KALV, the case for buying here is modest. A 1.0% spread on a 3-5 month hold annualizes to roughly 4-6% — fine versus cash, but unspectacular, and any timing slippage erodes it further. Without an odd-lot provision, there is no enhanced angle for small portfolios.

If you do own KALV, holding through close is the path of least resistance. The board's unanimous recommendation, the absence of a financing condition, and the low-friction regulatory path mean the most likely outcome is collecting $27.00 per share in Q3 2026. Tendering early once the Schedule TO is filed gets you paid sooner; sitting tight through the Section 251(h) squeeze-out gets you the same price slightly later.

The thesis here is "high probability, low premium remaining." The market has done most of the work. What's left is collecting the last percent.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.